New device may reduce radiation exposure to patients with liver cancer
the ONA take:
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer undergoing intra-arterial therapy (IAT), according to a report to be presented at the Radiological Society of North America annual meeting in Chicago.
In a clinical trial, Jean-Francois Geschwind, MD, and fellow researchers at Johns Hopkins University School of Medicine and Kimmel Cancer Center used the device on 50 patients, the researchers found that it was able to reduce exposure by up to 80 percent compared to standard X-ray platforms for IAT. In addition, AlluraClarity produced images that were just as clear as the standard system.
Dr. Geschwind believes that the novel platform will be especially useful in patients who require repeat therapy and are especially vulnerable to radiation such as children, as well as physicians who are regularly exposed to radiation procedures.
AlluraClarity uses a series of real-time image processing algorithms in order to achieve high quality images that require lower radiation power. It is developed by Philips Healthcare.
AlluraClarity has the potential to reduce radiation exposure in patients with liver cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|